文献速递冠心病外科

CABG术后双联抗血小板治疗对1年结局的影响:ART试验事后分析

Impact of dual antiplatelet therapy after coronary artery bypass surgery on 1-year outcomes in the Arterial Revascularization Trial.
PubMed 文献 · Eur J Cardiothorac Surg · 2017-01-01

该研究为ART试验的事后分析,比较CABG术后出院时使用DAPT(氯吡格雷)与单用阿司匹林对1年结局的影响。倾向性评分匹配后,DAPT组与单药组MACCE发生率均为5.6%(HR 0.97,95%CI 0.59-1.59;P=0.90),出血差异匹配后不再显著。

要点

  • CABG术后出院时使用DAPT(氯吡格雷)较单用阿司匹林未显著降低1年MACCE。
  • 匹配后DAPT组与单药组MACCE均为5.6%,出血差异不再显著。
  • 仅31%受试者完成1年DAPT,该亚组MACCE亦无显著差异。

核心结论

  • 与单用阿司匹林相比,CABG术后出院时处方DAPT(氯吡格雷)未显著降低1年不良心脑血管事件。

研究设计与样本

  • ART试验事后分析,纳入ART试验患者n=3102,出院时DAPT 609例(21%)、单用阿司匹林2308例(79%),采用倾向性评分匹配。

主要发现

  • 609对匹配患者中,DAPT组与单药组MACCE均发生34例(5.6%),HR 0.97,95%CI 0.59-1.59,P=0.90。
  • 仅188例(31%)完成1年DAPT,该亚组MACCE率5.8%(HR 1.11,95%CI 0.53-2.30;P=0.78)。
  • 总体样本中DAPT组出血率高于单药组(2.3% vs 1.1%;P=0.02),匹配后差异不再显著(2.3% vs 1.8%;P=0.54)。

关键数值与推荐

  • 主要终点为1年MACCE,含心源性死亡、心肌梗死、脑血管事件和再干预;安全终点为需住院的出血。
  • 匹配后MACCE组间无显著差异:HR 0.97,95%CI 0.59-1.59;P=0.90。

临床怎么用

  • 现有证据不支持CABG术后常规处方DAPT(氯吡格雷)以降低1年MACCE,应结合缺血与出血风险个体化决策。

局限性

  • 为事后分析,非随机分组;DAPT依从性低,仅31%完成1年DAPT。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: There is still little evidence to boldport routine dual antiplatelet therapy (DAPT) with P2Y12 antagonists following coronary artery bypass grafting (CABG). The Arterial Revascularization Trial (ART) was designed to compare 10-year survival after bilateral versus single internal thoracic artery grafting. We aimed to get insights into the effect of DAPT (with clopidogrel) following CABG on 1-year outcomes by performing a post hoc ART analysis. METHODS: Among patients enrolled in the ART (n = 3102), 609 (21%) and 2308 (79%) were discharged on DAPT or aspirin alone, respectively. The primary end-point was the incidence of major adverse cerebrovascular and cardiac events (MACCE) at 1 year including cardiac death, myocardial infarction, cerebrovascular accident and reintervention; safety end-point was bleeding requiring hospitalization. Propensity score (PS) matching was used to create comparable groups. RESULTS: Among 609 PS-matched pairs, MACCE occurred in 34 (5.6%) and 34 (5.6%) in the DAPT and aspirin alone groups, respectively, with no significant difference between the 2 groups [hazard ratio (HR) 0.97, 95% confidence interval (CI) 0.59-1.59; P = 0.90]. Only 188 (31%) subjects completed 1 year of DAPT, and in this subgroup, MACCE rate was 5.8% (HR 1.11, 95% CI 0.53-2.30; P = 0.78). In the overall sample, bleeding rate was higher in DAPT group (2.3% vs 1.1%; P = 0.02), although this difference was no longer significant after matching (2.3% vs 1.8%; P = 0.54). CONCLUSIONS: Based on these findings, when compared with aspirin alone, DAPT with clopidogrel prescribed at discharge was not associated with a significant reduction of adverse cardiac and cerebrovascular events at 1 year following CABG.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Benedetto U, Altman DG, Gerry S, et al. Impact of dual antiplatelet therapy after coronary artery bypass surgery on 1-year outcomes in the Arterial Revascularization Trial. Eur J Cardiothorac Surg. 2017. PMID: 28387790. doi:10.1093/ejcts/ezx075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。